BDSX Biodesix Inc stock chart & analysis

Conviction 36HealthcareScan · Fri, Nov 6, 2026

Biodesix Inc (BDSX) closed at $8.53 (-57.01%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 18, RS Rating 52, -73.3% from its 52-week high, +25.6% year to date. Sector: Healthcare · Services-Medical Laboratories.

BDSX$8.53-57.01%

ResistanceSupportVol 14Insider buy

Loading chart…

Biodesix IncServices-Medical Laboratorieswww.biodesix.com ↗

Price8.53

Change-57.01%

Gap-37.40%

Rel volume25.28×

Avg volume186.05K

Avg $ vol2.72M

SMA 2022.31

SMA 5025.53

SMA 20018.90

Price vs 50-66.55%

Price vs 200-54.81%

MA stackmixed

50/200 cross—

Supertrenddown · 19.05

RSI (14)18

MACD hist-0.96

MACD cross—

Stoch %K / %D3 / 14

ADX (14)28

+DI / −DI8 / 49

RSI divergence—

MACD divergence—

ATR %31.05%

ADR %9.97%

52w high31.97

52w low5.26

From 52w high-73.29%

Above 52w low+62.36%

New 52w highNo

SqueezeOff

Bollinger width62.87%

%B-0.48

Donchian pos2.90%

Donchian high26.62

Donchian low8.00

AVWAP (52w high)18.72

vs AVWAP high-54.37%

AVWAP (52w low)10.44

vs AVWAP low-18.18%

OBV trendDown

Chaikin MF (20)-0.50

Today vs 20d25.28×

Avg vol (14d)241.11K

Avg vol (20d)186.05K

Avg $ vol (20d)2.72M

Market cap94.7M

RS Rating52 / 99

RS 3m (vs SPY)-60.78%

RS 6m (vs SPY)-43.95%

RS line new highNo

Trend template4/8

Technical rank6.5

1 week-63.28%

1 month-66.68%

3 months-65.65%

6 months-44.26%

1 year-0.70%

YTD+25.59%

P/E-2.69

P/B10.92

P/S1.07

P/FCF-4.02

EPS-4.67

Div yield—

ROE-406.51%

ROA-37.54%

Debt/Eq5.76

Current2.96

EV/EBITDA-5.24

Gross margin—

Net margin-39.85%

Rev growth24.08%

EPS growth17.86%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value116.29M

Revenue24.04M

Net income-8.03M

Gross profit—

Free cash flow-23.53M

IndustryServices-Medical Laboratories

ExchangeNasdaq

Shares out10.36M

Employees334

ListedWed, Oct 28, 2020

Free float4.95M

Float %49.2%

Short interest—

Days to cover—

Short volume53.3%

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction36 / 100

Pattern quality—

Tech rank6.5 / 100

Group rank23 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance30.99

Support21.36

Days since event—

Candle confirm—

Financials as of Wed, Sep 30, 2026 · quarterly.

BDSX technical analysis

Trend

BDSX's moving averages are mixed — no clean uptrend or downtrend. It closed 66.5% below the 50-day ($25.53) and 54.8% below the 200-day ($18.90). ADX(14) at 28 points to a strong, established trend. It meets 4 of 8 trend-template criteria.

Momentum

RSI(14) is 18, in oversold territory. The MACD histogram is negative. Its RS Rating of 52 puts its weighted 12-month performance ahead of about 52% of the US market.

Volume and volatility

Volume on the latest session ran 25.3× its 20-day average. It trades about $2.7M a day on average. ATR(14) is $2.65, 31.1% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.50) shows distribution.

Key levels

The chart pattern's support is $21.36 and its resistance $30.99. The 52-week range is $5.26 to $31.97; price is 73.3% below the high and 62.4% above the low. The VWAP anchored at the 52-week high is $18.72, above price.

Performance

BDSX returned -63.3% (1 week), -66.7% (1 month), -65.6% (3 months), -44.3% (6 months), -0.7% (1 year), +25.6% (year to date).

About Biodesix Inc

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

Services-Medical Laboratories · Listed 2020 · 334 employees

Insider activity

SEC Form 4 transactions in BDSX · open-market 3 buys

Insider	Side	Shares	Value	Traded	Filed
PATIENCE JOHN Director · Common Stock · 2026-09-30	Exercise	1.36K	—	2026-09-30	2026-10-02
PATIENCE JOHN Director · Restricted Stock Units · 2026-09-30	Exercise	1.36K	—	2026-09-30	2026-10-02
SCHULER JACK W 10% owner · Common Stock · 2026-08-12	Buy	15K	$367K	2026-08-12	2026-08-13
SCHULER JACK W 10% owner · Common Stock · 2026-08-11	Buy	13.7K	$329K	2026-08-11	2026-08-12
SCHULER JACK W 10% owner · Common Stock · 2026-08-10	Buy	13.9K	$337K	2026-08-10	2026-08-12

SEC filings

EDGAR filings in BDSX · 7 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.